TD Cowen Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $115
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
TD Cowen analyst Nicholas Lorusso maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $100 to $115.
TD Cowen analyst Nicholas Lorusso maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $100 to $115.
